Philip Morris International Highlights Novel E-Vapor Technology in Latest Scientific Update for Smoke-Free Products
May 22 2017 - 9:04AM
Business Wire
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM)
today released its second Scientific Update for Smoke-Free
Products, a regular publication on its research efforts to develop
and assess a range of potentially reduced-risk alternatives to
cigarettes. The full issue is available here:
https://www.pmiscience.com/news/smoke-free-products-scientific-update.
This issue of the Scientific Update focuses on novel approaches
to e-vapor products. Technology and innovation can improve user
experience and continuously enhance a product’s potential to
present less risk of harm than smoking. The focus of the issue
details the product design and manufacturing behind MESH, the new
generation of e-vapor technology PMI is currently test marketing in
Birmingham (UK). MESH is one of the four smoke-free product types
developed by PMI, along with IQOS.
Prof. Manuel Peitsch, PMI’s Chief Scientific Officer, explains:
“PMI is working to progressively transition its existing cigarette
business to smoke-free products. By offering a diverse portfolio of
innovative and scientifically substantiated alternatives, we
believe we can accelerate the switching of an even greater number
of adult smokers who would otherwise continue to smoke and have a
positive impact on public health.”
Michele Cattoni, PMI’s VP Technology and Operations, further
elaborates on the Company’s efforts: “Technological innovation is
at the heart of PMI’s efforts to create a smoke-free future. We
have developed an e-vapor product which, like our other smoke-free
technologies, incorporates the highest manufacturing and design
standards to ensure the consistency and quality of the generated
vapor.”
Beyond the development behind PMI’s MESH proprietary technology,
the Update provides an overview of its assessment to date. The
issue also covers the latest studies, key peer-reviewed
publications and presentations at scientific conferences. It is an
important complement to PMI’s ongoing efforts to share its latest
science, which include a dedicated website
(www.pmiscience.com).
PMI’s extensive research and assessment program is inspired by
the well-recognized practices of the pharmaceutical industry and in
line with guidance of the U.S. FDA for Modified-Risk Tobacco
Products (MRTPs). The Company today employs over 400 world-class
scientists, engineers and experts who conduct rigorous research,
including laboratory and clinical studies, as well as
ground-breaking systems toxicology. The assessment program also
includes studies on actual product use and correct understanding of
product communications, as well as post-market research.
About Philip Morris International Inc. (“PMI”)
PMI is the world’s leading international tobacco company, with
six of the world's top 15 international brands and products sold in
more than 180 markets. In addition to the manufacture and sale of
cigarettes, including Marlboro, the number one global cigarette
brand, and other tobacco products, PMI is engaged in the
development and commercialization of reduced-risk products
(“RRPs”). RRPs is the term PMI uses to refer to products that
present, are likely to present, or have the potential to present
less risk of harm to smokers who switch to these products versus
continued smoking. Through multidisciplinary capabilities in
product development, state-of-the-art facilities, and
industry-leading scientific substantiation, PMI aims to provide an
RRP portfolio that meets a broad spectrum of adult smoker
preferences and rigorous regulatory requirements. For more
information, see www.pmi.com and www.pmiscience.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170522005754/en/
Media enquiriesPhilip Morris International media officeT: +41
(0)58 242 4500E: media@pmi.com
Philip Morris (NYSE:PM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Philip Morris (NYSE:PM)
Historical Stock Chart
From Apr 2023 to Apr 2024